XNAS · Healthcare · Biotechnology
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q3 2026 | -0.16 | -0.16 | +0.00% | $0 | ➖ Inline | -0.60% | -6.06% | — |
| 2026-02-12 | Q2 2026 | -0.17 | -0.22 | -29.41% | $0 | ❌ Miss | -3.58% | -9.64% | -28.51% |
| 2025-11-06 |
| Q1 2026 |
| -0.27 |
| -0.18 |
| +33.33% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-09-17 | Q4 2025 | -0.23 | -0.26 | -13.04% | — | ❌ Miss | — | — | — |
| 2025-02-12 | Q2 2025 | -0.25 | -0.22 | +12.00% | $0 | ✅ Beat | -1.03% | -6.38% | -25.93% |
| 2024-11-07 | Q1 2025 | -0.33 | -0.22 | +33.33% | $0 | ✅ Beat | -2.45% | -2.10% | -12.24% |
| 2024-09-19 | Q4 2024 | -0.33 | -0.44 | -33.33% | $0 | ❌ Miss | +5.39% | +1.24% | +1.45% |
| 2024-05-15 | Q3 2024 | -0.31 | -0.34 | -9.68% | $0 | ❌ Miss | -3.40% | +6.04% | +49.06% |
Showing last 8 quarters.